Analysis Of Backdoor Stock Analysis And Its Impact On Financial Performance

In recent years,China's economic strength has increased,and people's living standards have improved significantly.People's increasing demand for medicines,coupled with the support of national policies,has brought great opportunities and challenges to the pharmaceutical industry.However,the pharmaceutical industry is a high-tech industry and needs a lot of funds to support the expenditures for medical R&D and the expenditures for production.Therefore,in order to promote the development of pharmaceutical companies,raising funds has become the first choice.In China,most pharmaceutical companies raise funds through the listing approach.There are two methods of listing in our country.The first is IPO listing,and the second is backdoor listing.Backdoor listing is simpler and less time consuming than IPO listing.On the other hand,the approval rate for backdoor listing is higher than the IPO adoption rate.Therefore,backdoor listing has become the best choice for listing for the pharmaceutical industry.This article analyzes the case of Jialin Pharmaceutical's backdoor Tianshan Textile,and specifically analyzes the motivation of its backdoor listing and its impact on financial performance.Because Jialin Pharmaceutical is a leading manufacturer of descending cardiovascular and cerebrovascular diseases in China,it has a certain representation on the market.The writing idea of this paper is to distinguish the definition of a series of professional terms such as shell and shell company firstly,secondly,the domestic and foreign research results on the causes of backdoor listing and the influence of performance are analyzed.Finally,the backdoor of Jialin Pharmaceutical was analyzed.Using financial analysis methods and economic value-added methods to evaluate changes in the business performance of Jialin Pharmaceutical after the backdoor listing.The conclusions drawn from this paper are as follows:Jialin Pharmaceutical partially achieved its backdoor listing.The backdoor listing did not have a positive effect on the financial performance of Jialin Pharmaceutical.In the end,this paper puts forward three suggestions:the first is to speed up product development and invest more R&D funds;the second is to start the "industry + capital" two-wheel drive model,and finally strengthen the training and management of dealers,upgrade and maintain Brand.